In addition, the study also suggested that abnormal bone marrow stroma may result in the acquisition of BCR–ABL1 and other genetic aberrations, leading to MDS or AML.[6] Therefore, in addition to the molecular detection of BCL/ABL in CML, which used to be the main monitor for response to TKI therapy, cytogenetic analysis or next-generation sequencing of CML patients should be performed. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.